Free Trial

Apellis Pharmaceuticals (APLS) Competitors

Apellis Pharmaceuticals logo
$28.31 +1.24 (+4.58%)
Closing price 04:00 PM Eastern
Extended Trading
$28.13 -0.18 (-0.64%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

APLS vs. RDY, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, VRNA, RVMD, and ABVX

Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

Apellis Pharmaceuticals vs. Its Competitors

Dr. Reddy's Laboratories (NYSE:RDY) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Dr. Reddy's Laboratories has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$3.81B3.23$663M$0.6622.34
Apellis Pharmaceuticals$781.37M4.58-$197.88M-$1.82-15.55

Dr. Reddy's Laboratories presently has a consensus target price of $16.95, indicating a potential upside of 14.95%. Apellis Pharmaceuticals has a consensus target price of $33.47, indicating a potential upside of 18.23%. Given Apellis Pharmaceuticals' higher possible upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.83
Apellis Pharmaceuticals
2 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.47

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

In the previous week, Apellis Pharmaceuticals had 20 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 23 mentions for Apellis Pharmaceuticals and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.28 beat Apellis Pharmaceuticals' score of 0.32 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Apellis Pharmaceuticals
8 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Dr. Reddy's Laboratories has a net margin of 16.99% compared to Apellis Pharmaceuticals' net margin of -30.24%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Apellis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories16.99% 17.25% 11.63%
Apellis Pharmaceuticals -30.24%-116.09%-26.72%

Summary

Dr. Reddy's Laboratories beats Apellis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Apellis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLS vs. The Competition

MetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.42B$3.48B$6.18B$10.69B
Dividend YieldN/A2.26%5.72%4.83%
P/E Ratio-15.558.2420.7722.98
Price / Sales4.58481.95579.80129.94
Price / CashN/A47.5937.5161.65
Price / Book15.3910.6612.476.59
Net Income-$197.88M-$52.56M$3.32B$276.14M
7 Day Performance22.29%4.97%1.87%0.01%
1 Month Performance23.03%16.48%8.40%3.60%
1 Year Performance5.32%14.95%63.49%32.76%

Apellis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLS
Apellis Pharmaceuticals
4.1007 of 5 stars
$28.31
+4.6%
$33.47
+18.2%
-3.3%$3.42B$781.37M-15.55770Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.8006 of 5 stars
$14.36
+0.1%
$16.95
+18.1%
-7.5%$11.97B$3.81B21.7527,811
VTRS
Viatris
3.5019 of 5 stars
$9.86
+1.2%
$10.40
+5.5%
-12.3%$11.36B$14.74B-3.4032,000
ROIV
Roivant Sciences
2.7111 of 5 stars
$16.21
+1.1%
$19.94
+23.0%
+48.8%$10.95B$29.05M-23.16860
BBIO
BridgeBio Pharma
4.6007 of 5 stars
$55.96
+0.8%
$63.94
+14.3%
+116.2%$10.61B$221.90M-13.68400Analyst Forecast
MRNA
Moderna
4.2934 of 5 stars
$26.74
-0.3%
$41.81
+56.4%
-49.6%$10.48B$3.24B-3.555,800Trending News
Analyst Forecast
QGEN
QIAGEN
4.1823 of 5 stars
$47.30
+1.0%
$49.40
+4.4%
+16.5%$10.41B$1.98B27.955,765Positive News
ELAN
Elanco Animal Health
2.7355 of 5 stars
$20.04
+1.4%
$19.14
-4.5%
+67.7%$9.82B$4.44B23.309,000Analyst Forecast
VRNA
Verona Pharma PLC American Depositary Share
1.5784 of 5 stars
$106.91
flat
$109.00
+2.0%
N/A$9.21B$42.28M-107.9930Positive News
RVMD
Revolution Medicines
4.4666 of 5 stars
$48.75
+1.1%
$74.64
+53.1%
+7.1%$9.02B$11.58M-10.83250Analyst Forecast
ABVX
Abivax
3.5852 of 5 stars
$95.63
+2.0%
$114.25
+19.5%
+775.5%$7.30BN/A0.0061Short Interest ↓
Gap Up

Related Companies and Tools


This page (NASDAQ:APLS) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners